Additional biospecimen analysis is planned once all cohorts are completed and will include quantifying TRT dose-dependent effects on tumor-infiltrating immune cells, expression of immune susceptibility markers, expression of markers of T cell exhaustion (PD-1, CTLA-4 and Tim3), effector function (IFN-γ and TNF) in the TME, and quantification of T cell receptor (TCR) diversity. The gene discussed is TNF; the disease is neoplasm.